Rituximab Binding Endows CD20+ Extracellular Vesicles With NK Cell-Activating Properties in B Cell Lymphoma

Area of Science:

• Immunology
• Oncology
• Cell Biology

Background:

• Non-Hodgkin lymphoma (B-NHL) treatment relies on chemotherapy and rituximab (RTX).
• Treatment resistance and relapse remain significant challenges in B-NHL management.
• The tumor microenvironment's role in RTX efficacy is not fully understood.

Purpose of the Study:

• To investigate if CD20+ extracellular vesicles (EVs) from B-NHL influence RTX efficacy.
• To explore the interaction between RTX, CD20+ EVs, and natural killer (NK) cell activity.

Main Methods:

• Isolation of EVs from B-NHL patient samples (lymph nodes, plasma).
• Characterization of CD20 expression on EVs.
• Assessment of RTX binding to CD20+ EVs.
• Functional assays measuring NK cell activation and cytotoxicity upon exposure to EVs and EV-RTX complexes.

Main Results:

• CD20+ EVs were abundant in B-NHL samples, especially in advanced disease.
• RTX bound to CD20 on EVs, forming EV-RTX immune complexes.
• EV-RTX complexes reversed EV-mediated NK cell suppression and enhanced NK cell effector functions, including cytotoxicity.
• Activation was dependent on FcγRIIIa, indicated by Syk phosphorylation and CD69 expression.

Conclusions:

• RTX binding to CD20+ EVs generates immune complexes that activate NK cells.
• This interaction represents a novel mechanism potentially enhancing RTX therapeutic efficacy in B-NHL.
• Antibody binding can confer immunomodulatory properties to EVs, influencing anti-tumor immunity.